KRAS and Cirrhosis: Among patients treated with the glecaprevir/pibrentasvir regimen, baseline polymorphisms in NS3 or NS5A, including the prevalent NS3-Q80K polymorphism in GT1a, had no impact on treatment outcome, regardless of treatment duration, prior treatment history, or cirrhosis status for patients infected with GT1, -2, -4, -5, or -6.